BHBaraa. Hamze

Baraa. Hamze

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Baraa. Hamze has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protective Effects of N-Acetylcysteine Plus Coenzyme Q10 Combination Against Atorvastatin-Induced Toxicity: Evidence from In Vivo and In Vitro Experimental Models

    by Baraa. Hamze, Engin Sümer, Alev Cumbul, Ela Naz Köprülü, Muhammed Hamitoğlu, Hande Sipahi, Issam Kassab, Fouad Dabboussi, Ahmet Aydın

    Atorvastatin, a widely prescribed HMG-CoA reductase inhibitor, causes statin-associated muscle symptoms and, less commonly, hepatic and renal toxicity, effects attributed to mitochondrial dysfunction and oxidative stress; strategies to prevent this multisystem injury are needed. This study evaluated whether N-acetylcysteine (NAC) and coenzyme Q10 (CoQ10), alone and in combination, protect against atorvastatin-induced toxicity in male BALB/c mice and C2C12 myoblasts. Mice (n = 30) received, by oral gavage once daily for 14 days, vehicle, atorvastatin (100 mg/kg/day), atorvastatin plus NAC (200 mg/kg/day), atorvastatin plus CoQ10 (100 mg/kg/day), or the triple combination. Outcomes included survival, body weight, rotarod performance, serum creatine kinase, erythrocyte oxidative-stress markers, semi-quantitative histopathology, TUNEL apoptosis, and VEGF immunohistochemistry in liver, kidney, and skeletal muscle, complemented by in vitro atorvastatin cytotoxicity and antioxidant cytoprotection assays in C2C12 myoblasts (atorvastatin 50–200 µg/mL; CoQ10 12.5–50 µg/mL; NAC 100–400 µg/mL). Atorvastatin produced significant histopathological injury and increased apoptotic and VEGF immunoreactivity in all three tissues (p < 0.0001–0.005), effects markedly attenuated by combined NAC plus CoQ10. Glutathione peroxidase activity was significantly reduced by atorvastatin and restored by combination therapy (p < 0.05); catalase, malondialdehyde, and superoxide dismutase showed non-significant favorable trends. In C2C12 myoblasts, atorvastatin produced concentration-dependent cytotoxicity (IC50 ≈ 65 µg/mL), substantially reversed by NAC plus CoQ10 (≈89% viability restoration, p = 0.0025). These findings indicate that combined NAC and CoQ10 confer structural, apoptotic, and cytoprotective protection against atorvastatin-induced toxicity, supporting further mechanistic and translational investigation of combined antioxidant strategies in this high-dose supratherapeutic model; extrapolation to routine clinical statin intolerance will require confirmation at clinically relevant exposures.

  • Open Access

    Source-Dependent Renal Effects of Commercial Protein Supplements: A 28-Day Study in Rats

    by Engin Sümer, Elif Nur Sarıalioğlu, Ayşe Aksan, Baraa Hamze, Aysun Özbay Önal, Muhammed Hamitoğlu, Ahmet Aydın

    Background and Objectives: Commercial protein powders are widely consumed to increase dietary protein intake, yet whether their renal effects differ by protein source remains poorly characterized. The primary objective of this study was therefore to determine whether 28 days of administration of commercial whey, casein, soy or beef protein powder produces source-dependent renal histopathological injury in rats, with the total renal injury score as the primary outcome. Secondary objectives were to assess conventional renal function markers and the renal oxidative stress response. Materials and Methods: Thirty-five female Sprague Dawley rats were stratified by body weight and randomly assigned to five groups (n = 7 per group): control, whey, casein, soy and beef. The powders were given by oral gavage in 0.9% sterile isotonic saline at 400 mg/kg/day of protein for 28 consecutive days; controls received the vehicle only. Body weight, kidney-to-body weight ratio, serum urea and creatinine, urinalysis, renal histopathology, renal oxidative stress parameters and the elemental composition of the powders were assessed. Results: Protein supplementation did not significantly affect body weight, kidney-to-body weight ratio, serum urea, creatinine or urinalysis findings in any group. Despite this, renal responses differed by protein source. All powders produced mild-to-moderate tubular change relative to the control. The beef group showed the highest total injury score and was the only group that differed from control in every parameter, although the protein groups did not differ from one another. The oxidative response also differed by source: renal malondialdehyde (MDA) was highest in the beef group and significantly exceeded the casein and soy groups, whereas catalase (CAT) activity was significantly reduced in the whey and casein groups. Glutathione peroxidase (GSH-Px) and nitrite levels were unchanged. Estimated metal exposure from all powders remained below toxicological risk thresholds. Conclusions: The renal effects of commercial protein powders are source-dependent even at a low dose and in the absence of any change in conventional renal function markers. Beef protein was associated with the highest lipid peroxidation and casein with the largest fall in enzymatic antioxidant capacity, two distinct oxidative signatures. These effects, and their progression under longer-term exposure, warrant further investigation.